Live
FierceBiotechBiopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?Promega BlogCharged Molecular Glues: The Molecular Trojan Horse That Slipped Past Biology’s Toughest BouncerClinical OMICsContact Lenses Show Promise for DepressionEndpoints NewsDegron, CREATE, TenNor raise capital; Cabaletta posts CAR-T dataEndpoints NewsAstraZeneca follows Merck with Phase 3 win in bladder cancerEndpoints NewsMacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attackFierceBiotechCreate Medicines fashions $122M fundraise for in vivo CAR-T dreamsBioPharma DiveWith new data, Regenxbio to seek FDA approval of Duchenne gene therapyEndpoints NewsHow Penn Medicine plans to use AI to train their doctorsFierceBiotechBiogen advances Alzheimer’s tau program despite midphase missBioWorldSanofi synthesizes new ERK5 inhibitorsBioWorldSironax patents new SARM1 inhibitors
Endpoints News Mar 30, 2026

#AAD26: Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcoma

#AAD26: Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcoma

Original
Body unavailable. Use the original source.